IWC - iShares Micro-Cap ETF
| Previous Close | 103.930 |
| Open | 103.990 |
| Bid | 0.000 x 800 |
| Ask | 0.000 x 900 |
| Day's Range | 103.313 - 104.130 |
| 52 Week Range | 83.450 - 104.350 |
| Volume | 34,613 |
| Avg. Volume | 36,035 |
| Net Assets | 910M |
| NAV | 97.33 |
| PE Ratio (TTM) | N/A |
| Yield | 1.07% |
| YTD Return | 1.91% |
| Beta (3y) | 0.98 |
| Expense Ratio (net) | 0.60% |
| Inception Date | 2005-08-12 |
- CNBC Videos•2 months ago
Reawakening risk appetites
CNBC's Mike Santoli takes a look at ETFs tracking some riskier sectors that investors are putting their faith into.
- CNBC•5 days ago
Three ways to profit from the soaring dollar
As the greenback soars to its highest levels of the year, one trader sees a couple of market areas that could ride the currency's coattails. "I will caution one thing" on the IWM, said Cappelleri. The U.S. dollar index has not traded above 94 since December 2017.
- CNBC•5 days ago
Three ways to profit from the soaring dollar
As the greenback soars to its highest levels of the year, one trader sees a couple of market areas that could ride the currency's coattails.
- Market Realist•2 months ago
Comparing the Short Interest in the Top 5 OFS Companies
Top 5 Oilfield Companies Based on 2018 Returns
Market Realist•4 months agoAnalysts’ Recommendations for Cara Therapeutics in January 2018
Cara Therapeutics (CARA) is a clinical-stage biopharmaceutical company focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by targeting peripheral kappa opioid receptors in affected patients. The company is developing a novel class of product candidates that target the body’s peripheral nervous system and certain immune cells. Of the seven analysts covering Cara Therapeutics in January 2018, six analysts gave the stock a “buy” or higher rating, and one recommended “hold.” The stock has a mean rating of 1.9 and a target price of $24.29.
- Market Realist•4 months ago
Arrowhead’s Candidates for Hepatitis B, Cardiovascular Diseases
Arrowhead Pharmaceuticals: A Promising Drug Pipeline
- Market Realist•9 months ago
Wall Street Analysts’ Recommendations for Flotek Industries
On August 10, 2017, all of the sell-side analysts tracking Flotek Industries rated it as a “buy.” None of the analysts rated Flotek as a “hold” or “sell.”
- Market Realist•9 months ago
How Flotek Industries’ 2017 Capex Plans Changed
Flotek Industries’ (FTK) cash from operating activities (or CFO) remained negative in 2Q17, continuing with a negative cash flow trend in 1Q17.
- Market Realist•9 months ago
How Rig Count and Upstream Operator Capex Affected FTK
From 2Q16 to 2Q17, Flotek Industries’ (FTK) EBITDA margin (or EBITDA as a percentage of revenues) improved to 2.3% from 0.7%.
- TheStreet.com•11 months ago
A Macro Look at How the Income-Minded Can Gain Exposure to Micro-Caps
Besides owning micro-cap stocks directly, there are mutual funds and exchange-traded funds.
- Market Realist•11 months ago
Inside Flotek Industries’ New 2017 Capex Plan
Flotek's (FTK) CFO (cash from operating activities) was negative in 1Q17, after being positive for three quarters. FTK’s CFO was -$2.5 million in 1Q17.
- Market Realist•11 months ago
How Flotek Could React to Upstream Operators’ Capex and the Rig Count
From 1Q16 to 1Q17, Flotek’s EBITDA margin shrank to 3.3% from 4.1%. FTK’s EBITDA margin has been 1.7%, on average, for the past five quarters.
- Zacks•11 months ago
Small Caps Outperform in June: 4 Best ETFs & Stocks
Small cap stocks have regained their sheen and outperformed the broader U.S. market in June.
